Who’s Hired? Henlius’ Liu Joins Eden Biologics
As Senior FDA Official Joins King & Spalding
Eden Biologics adds Henlius’ Scott Liu to its board of directors, as both King & Spalding and Gedeon Richter also make fresh appointments. And Stada has extended the tenure of CEO Peter Goldschmidt.
You may also be interested in...
Former senior FDA official Eva Temkin has criticized the FDA’s silence on the development of biosimilars and interchangeable products in its recent COVID-19 guidance, suggesting that the agency’s stance on 180-day exclusivity for small-molecule generics could be extended to interchangeability exclusivity for biosimilars, while also pointing out that key questions around generic exclusivity are left unanswered
As Michael Sen takes the reins as CEO of Fresenius Kabi, Christian Pawlu has been recruited from Sandoz to head up the firm’s generics and complex formulations unit.
The AAM has applauded US proposals to lower drug prices, following the development of the HHS’s 45-day plan in response to president Joe Biden’s executive order on promoting competition. However, AAM chief executive Dan Leonard has criticized Congressional proposals to weaken the 180-day incentive for first generics and curtail patent settlement agreements as “misguided.”